ArticleFrontiers in neuroscience2026
Tenecteplase versus standard medical treatment for minor stroke due to anterior-circulation medium-vessel occlusion: a multicenter observational study.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess whether intravenous tenecteplase is associated with improved clinical outcomes compared with standard medical treatment (SMT) in patients with minor acute ischemic stroke (AIS) caused by medium-vessel occlusion (MeVO). Methods: We conducted a multicenter, retrospective observational study of consecutive patients with minor AIS, defined as a National Institutes of Health Stroke Scale score <6, and imaging-confirmed anterior-circulation MeVO. Patients were classified into the tenecteplase group or the SMT group (without intravenous thrombolysis) based on their initial treatment strategy. The primary outcome was excellent functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 0-1. Secondary outcomes included functional independence at 90 days (mRS 0-2). Inverse probability of treatment weighting (IPTW)-adjusted analyses were performed to balance measured baseline characteristics between groups. Results: A total of 216 patients were included, of whom 64 received tenecteplase and 152 received SMT. After IPTW adjustment, tenecteplase was associated with a higher likelihood of excellent functional outcome at 90 days compared with SMT (70.3% vs. 53.3%; adjusted odds ratio [aOR], 2.07; 95% confidence interval [CI], 1.11-3.87). Tenecteplase was also associated with a higher rate of functional independence at 90 days (mRS 0-2: 81.3% vs. 64.5%; aOR, 2.39; 95% CI, 1.18-4.87). No statistically significant differences were observed in hemorrhagic transformation (5.2% vs. 7.0%) or symptomatic intracranial hemorrhage (3.4% vs. 4.3%). Conclusion: Among patients with minor AIS caused by anterior-circulation MeVO, tenecteplase was associated with better functional outcomes, without an apparent increase in hemorrhagic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.